ZA202300822B - Methods for the use of a pd-1 x ctla-4 bispecific molecule - Google Patents
Methods for the use of a pd-1 x ctla-4 bispecific moleculeInfo
- Publication number
- ZA202300822B ZA202300822B ZA2023/00822A ZA202300822A ZA202300822B ZA 202300822 B ZA202300822 B ZA 202300822B ZA 2023/00822 A ZA2023/00822 A ZA 2023/00822A ZA 202300822 A ZA202300822 A ZA 202300822A ZA 202300822 B ZA202300822 B ZA 202300822B
- Authority
- ZA
- South Africa
- Prior art keywords
- ctla
- bispecific molecule
- methods
- cancer
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057054P | 2020-07-27 | 2020-07-27 | |
| US202163177036P | 2021-04-20 | 2021-04-20 | |
| US202163219066P | 2021-07-07 | 2021-07-07 | |
| PCT/US2021/042901 WO2022026306A1 (en) | 2020-07-27 | 2021-07-23 | Methods for the use of a pd-1 x ctla-4 bispecific molecule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202300822B true ZA202300822B (en) | 2023-08-30 |
Family
ID=80036053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/00822A ZA202300822B (en) | 2020-07-27 | 2023-01-18 | Methods for the use of a pd-1 x ctla-4 bispecific molecule |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230312756A1 (https=) |
| EP (1) | EP4188961A4 (https=) |
| JP (1) | JP2023536086A (https=) |
| KR (1) | KR20230042038A (https=) |
| CN (1) | CN116134053A (https=) |
| AU (1) | AU2021316192A1 (https=) |
| BR (1) | BR112023001487A2 (https=) |
| CA (1) | CA3189926A1 (https=) |
| IL (1) | IL300166A (https=) |
| MX (1) | MX2023001111A (https=) |
| TW (1) | TW202220691A (https=) |
| WO (1) | WO2022026306A1 (https=) |
| ZA (1) | ZA202300822B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120648657A (zh) * | 2024-03-08 | 2025-09-16 | 上海锦斯生物技术有限公司 | 一种修饰的溶瘤病毒及其组合物 |
| WO2026021409A1 (zh) * | 2024-07-22 | 2026-01-29 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| IL260021B (en) * | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| AR108377A1 (es) * | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| JP7010854B2 (ja) * | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| WO2019179421A1 (en) * | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/ctla-4 antibody molecules |
-
2021
- 2021-07-23 TW TW110127252A patent/TW202220691A/zh unknown
- 2021-07-23 IL IL300166A patent/IL300166A/en unknown
- 2021-07-23 CN CN202180059321.7A patent/CN116134053A/zh active Pending
- 2021-07-23 BR BR112023001487A patent/BR112023001487A2/pt unknown
- 2021-07-23 JP JP2023505707A patent/JP2023536086A/ja active Pending
- 2021-07-23 WO PCT/US2021/042901 patent/WO2022026306A1/en not_active Ceased
- 2021-07-23 US US18/006,294 patent/US20230312756A1/en active Pending
- 2021-07-23 EP EP21849290.8A patent/EP4188961A4/en active Pending
- 2021-07-23 CA CA3189926A patent/CA3189926A1/en active Pending
- 2021-07-23 KR KR1020237004873A patent/KR20230042038A/ko active Pending
- 2021-07-23 AU AU2021316192A patent/AU2021316192A1/en active Pending
- 2021-07-23 MX MX2023001111A patent/MX2023001111A/es unknown
-
2023
- 2023-01-18 ZA ZA2023/00822A patent/ZA202300822B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL300166A (en) | 2023-03-01 |
| MX2023001111A (es) | 2023-03-07 |
| US20230312756A1 (en) | 2023-10-05 |
| EP4188961A1 (en) | 2023-06-07 |
| KR20230042038A (ko) | 2023-03-27 |
| TW202220691A (zh) | 2022-06-01 |
| CA3189926A1 (en) | 2022-02-03 |
| AU2021316192A1 (en) | 2023-02-23 |
| BR112023001487A2 (pt) | 2023-02-14 |
| CN116134053A (zh) | 2023-05-16 |
| WO2022026306A1 (en) | 2022-02-03 |
| JP2023536086A (ja) | 2023-08-23 |
| EP4188961A4 (en) | 2024-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007790A (es) | Terapia para el tratamiento del cancer. | |
| EP4501352A3 (en) | Compositions and methods for car t cell therapy | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| MX2024013525A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t | |
| ZA202300822B (en) | Methods for the use of a pd-1 x ctla-4 bispecific molecule | |
| SA522433129B1 (ar) | مركب بيريدازينيل-ثيازول كربوكساميد | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| EA202190181A1 (ru) | Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1 | |
| BR112022002831A2 (pt) | Formulações anti-c5 de alta concentração | |
| MX2019002474A (es) | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. | |
| MA44547A1 (fr) | Anticorps anti-pd-1,procédé de leur production et de leur utilisation | |
| PH12022553153A1 (en) | Binding molecules for the treatment of cancer | |
| MX2021005236A (es) | Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer. | |
| EA201892797A1 (ru) | Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака | |
| MX2020002301A (es) | Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico. | |
| WO2023097194A3 (en) | Bicyclic therapeutic compounds and methods of use in the treatment of cancer | |
| WO2019136157A3 (en) | Reducing beta-catenin and ido expression to potentiate immunotherapy | |
| ZA202211455B (en) | Methods for the use of a b7-h3 antibody-drug conjugate alone or in combination | |
| MX2024015058A (es) | Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer | |
| PH12021551419A1 (en) | New conjugated nucleic acid molecules and their uses | |
| MX2021005266A (es) | Regimen de dosificacion del anticuerpo anti-gen de activacion de linfocitos 3 (anti-lag3) y terapia combinada con anticuerpo anti-muerte progamada-1 (anti-pd-1) para el tratamiento del cancer. | |
| PH12022552041A1 (en) | Anti-axl antibodies and compositions | |
| MX2020002266A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos. | |
| WO2019190927A3 (en) | Splice-switching oligonucleotides and methods of use | |
| MX2024004429A (es) | Regimenes de dosificacion del anticuerpo anti-ctla-4. |